https://www.selleckchem.com/pr....oducts/proxalutamide
For patients indicating acceptable pain, the mean NRS was 1.6 (n=21,01. Although the presence of pain recorded in the patient record increased substantially over the year, the percentage of reported interventions only slightly increased. The (non) acceptable pain evaluation seems a valuable addition to the NRS for assessing pain among patients with cancer. As interpretation of the NRS appears to be difficult, using the (non) acceptable pain evaluation is recommended. Moreover, creating awareness among specialists to discu
Like
Comment
Share
